Drug Trial Radar · NCT05091346
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
89
Actual
Start
Oct 27, 2021
Primary completion
Oct 15, 2024
Study completion Oct 15, 2024
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with pembrolizumab. The Phase 2 part of this study is conducted to assess the objective response rate (ORR) of E7386 in combination with pembrolizumab (melanoma, colorectal cancer \[CRC\], hepatocellular carcinoma \[HCC\]) or of E7386 in combination with pembrolizumab plus lenvatinib (HCC) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Conditions
- Melanoma
- Carcinoma, Hepatocellular
- Colorectal Neoplasms
Interventions
E7386Drug
E7386 tablet.
PembrolizumabDrug
Pembrolizumab IV infusion.
LenvatinibDrug
Lenvatinib capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b Part: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Cycle 1 (Cycle length=21 days)
- Phase 1b Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 30 days after last dose of study drug (up to 12.73 months)
- Phase 1b Part: Number of Participants With Serious TEAEsTime frame: Up to 90 days after last dose of study drug (up to 14.73 months)
- Phase 2 Part: Objective Response Rate (ORR)Time frame: Up to 20.40 months
Locations
32 sites in 4 countries. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California
University of California, Irvine Health
Orange, California
Florida Cancer Specialists
Fort Myers, Florida
SCRI Florida Cancer Specialists East
West Palm Beach, Florida
Winship Cancer Institute
Atlanta, Georgia
Barbara Ann Karmanos Cancer Center
Detroit, Michigan
Rutgers cancer Institute of NJ
New Brunswick, New Jersey
Icahn School of Medicine at Mount Sinai
New York, New York
Providence Medical Center Institute Franz Clinic
Portland, Oregon
Tennessee Oncology PPLC
Nashville, Tennessee
Chiba University Hospital
Chiba, Japan
National Cancer Center Hospital
Chūōku, Japan
Kurume University Hospital
Fukuoka, Japan
National Cancer Center Hospital East
Kashiwa, Japan
Osaka Metropolitan University Hospital
Osaka, Japan
Kindai University Hospital
Ōsaka-sayama, Japan
Sapporo-Kosei General Hospital
Sapporo, Japan
Shizuoka Cancer Center Hospital
Shizouka, Japan
Toranomon Hospital
Tokyo, Japan
Hospital Universitario de Badajoz
Badajoz, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital General Universitario Gregorio Maranon
Madrid, Spain
Hospital Universitario de la Paz
Madrid, Spain
Consorcio Hospital General Universitario de Valencia
Valencia, Spain
Hospital Regional Universitario de Malaga
Málaga, Avenida Carolos Haya S/n, Spain
Hospital Clínico San Carlos
Madrid, Calle Profesor Martín Lagos, Spain
Clínica Universidad de Navarra
Pamplona, Navarre, Spain
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Imperial College London - Hammersmith Hospital
London, United Kingdom
Royal Free Hospital NHS Foundation Trust
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.